

**INNOVATIVE
MEDICAL
PROCEDURES AND
TECHNOLOGIES
ENABLE PATIENT
ACCESS**

Dimitris Nikas, President of BoD SEIV
Managing Director Medtronic Hellas



ΔΥΝΑΜΙΚΟΣ ΚΑΙ ΚΑΙΝΟΤΟΜΟΣ ΚΛΑΔΟΣ



Ιατροτεχνολογικός κλάδος



ΜΕΛΗ	ΠΩΛΗΣΕΙΣ 2021	ΠΟΣΟΣΤΟ ΑΓΟΡΑΣ	ΑΡ. ΕΤΑΙΡ	ΣΥΝΟΛΟ ΕΤΑΙΡ
ΜΕΛΗ ΣΕΙΒ	1.506.260.353 €	65,08%	128	174
ΕΚΤΟΣ ΣΕΙΒ	808.175.452 €	34,92%	239	333
ΣΥΝΟΛΟ	2.314.435.806 €	100,00%	367	507

Μερίδια Αγοράς 2021 (€)

ΕΚΤΟΣ ΣΕΙΒ
808.175.452 €




Μερίδια Αγοράς 2021 (%)

ΕΚΤΟΣ ΣΕΙΒ
35%



Graph 2 – Evolution of European patent applications and granted patents by technical field
2022 (ref 3.)



Healthcare systems face several challenges

Στηρίζουμε
την Έρευνα - τη Διάγνωση - τη Θεραπεία

Current reimbursement and access models have served Europe well but are now reaching their limit in ensuring timely patient access to truly cutting-edge technologies and services.

Therefore, it is time for innovative approaches to better integrate innovation into existing health systems. To that end, a new Value of Innovation and Partnership access model (or VIP for short) is proposed.

- European countries differ in the way access to medical procedures and medical technologies are provided. Typical payment (reimbursement) mechanisms include a global budget, diagnosis-related groups, and fee-for-service


To date, only a limited number of European countries have been able to introduce and administer innovative payment schemes: Austria, Belgium, England, France, Germany, the Netherlands, Spain, and Switzerland.

MDR- Urgent need for action on the medical technology regulations to ensure devices availability and competitiveness of the sector




























Seven years after their publication, the Medical Devices (MDR) and In Vitro Diagnostic Medical Devices (IVDR) Regulations¹ continue to hamper access to life-saving and life-sustaining medical technologies as they are plagued by inefficient and unpredictable processes, skyrocketing cost of compliance, insufficient support for innovation, and a lack of accountable governance


































Current access model in the EU – aspects of initial access, adoption, and uptake of medical technology innovation



Annex 1: European countries that have established Innovative Payment Schemes

Country	Innovative payment scheme	 Procedures	 Devices	 IVD	 Digital
	Provisional Codes for New Diagnostic or Therapeutic Methods (NUB)	●	●	●	●
	Restricted Clinical Application for invasive medical devices and implants	●	●	●	●
	Temporary Reimbursement of Software Applications (level 3-)	●	●	●	●
	Artificial Intelligence in Health & Care Award England (Phase 4)	●	●	●	●
	Innovation competition at the NHS Cancer Programme	●	●	●	●
	Medtech Funding Mandate	●	●	●	●
	Article 51 of the Social Security Financing Act	●	●	●	●
	Health Economic Research Program (PRME)	●	●	●	●
	Innovation Funding (Forfait Innovation)	●	●	●	●
	List of Biological and Anatomocytopathology Innovative Acts (RIHN) / Supplementary List	●	●	●	●
	Provisional Registration of Medical Procedures	●	●	●	●
	Transitional Coverage of medical devices	●	●	●	●
	G-BA Innovation Fund	●	●	●	●
	Government Co-Funded Clinical Studies (§137e framework)	●	●	●	●
	New Examination or Treatment Methods (NUB)	●	●	●	●
	Provisional listing of Digital Health Applications (DiGA)	●	●	●	●
	Small-Scale Experiments for the Introduction of Innovations	●	●	●	●
	Subsidy Scheme for Promising Care	●	●	●	●
	Monitoring Studies of Methods, Technologies, and Procedures	●	●	●	●
	Supervised Use of Methods, Technologies, and Procedures	●	●	●	●
	Provisional reimbursement of medical procedures	●	●	●	●
TOTAL		15	12	10	9

Annex 2: European countries/regions actively transforming their healthcare systems and/or the reimbursement and funding systems

Country	Initiative	Country	Initiative
	Structural reform of the INAMI/RIZIV Nomenclature		National HTA program for medical devices
	Integrated care plan		Introduction of a novel DRG system
	Reform of the organisation and financing of hospitals		Development of criteria of innovativeness of medical technologies
	Data for better health		Integrated funding for maternity care
	Development of the classification of hospitalization procedures		NordDEC: Cross-Border Digital Health Framework Programme
	Work plans for the Treatment Council		Safer health apps
	The NHS Innovation Service		New prioritisation criteria for the evaluation of medical technologies and procedures
	Multi-agency advisory service (MAAS) for artificial intelligence and data-driven technologies		Project "Implementation of the Hospital-Based HTA (HB-HTA) - Hospital Assessment of Innovative Medical Technologies"
	Health system development projects		New Statute of the National Health Service
	Reform of healthcare, social welfare, and rescue services		Accelerated National Innovation Adoption (ANIA) Pathway
	Reform of the reimbursement of telemonitoring and remote monitoring		National Institute for Health Technology Assessment
	Early Coverage framework for innovative digital medical devices		Expansion of the DRG system to cover services provided in day-case settings (JSZ)
	Revision of the CCAM Classification		Introduction of the novel payment system in out-patient care, TARDOC
	Ordinance on the Eligibility for Reimbursement of Digital Nursing Applications (VDiPA)		Lump-sum (DRG) payment system for outpatient surgery
	Pilot project genome sequencing		Genome UK: shared commitments for UK wide implementation 2022 to 2025
	Introduction of a novel DRG system		Innovative Devices Access Pathway
			Early Value Assessment program for MedTech

Greece-update

Reimbursement: DRG, Επιτροπή Διαπραγμάτευσης ΕΟΠΥΥ

HTA: Only Pharma

Innovation Budget: Only Pharma

Suppliers Registry: Pending

Eudamed-Product Registry: Pending

Digital adoption: Early stage

ΚΑΙΝΟΤΟΜΙΑ ΣΤΟ ΚΛΙΝΙΚΟ ΜΟΝΟΠΑΤΙ

